Tobramycin/dexamethasone: Difference between revisions
Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wik |
m Reverted edits by 105.71.135.50 (talk): not providing a reliable source (WP:CITE, WP:RS) (HG) (3.4.10) |
||
(50 intermediate revisions by 33 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Pharmaceutical preparation}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
|||
| verifiedrevid = |
| verifiedrevid = 477865033 |
||
⚫ | |||
<!--Combo data--> |
<!--Combo data--> |
||
⚫ | |||
| component1 = Tobramycin |
| component1 = Tobramycin |
||
| class1 = [[Aminoglycoside antibiotic]] |
| class1 = [[Aminoglycoside antibiotic]] |
||
Line 10: | Line 12: | ||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = Tobradex |
||
| Drugs.com = {{drugs.com|ppa|tobramycin-and-dexamethasone}} |
|||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
||
| pregnancy_US = C |
| pregnancy_US = C |
||
| pregnancy_US_comment = <ref name="Drugs.com pregnancy">{{cite web | title=Dexamethasone / tobramycin ophthalmic Use During Pregnancy | website=Drugs.com | date=28 November 2018 | url=https://www.drugs.com/pregnancy/dexamethasone-tobramycin-ophthalmic.html | access-date=13 September 2020}}</ref> |
|||
| pregnancy_category = |
| pregnancy_category = |
||
⚫ | |||
⚫ | |||
⚫ | |||
| ATC_suffix = CA01 |
|||
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
||
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
||
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
||
| legal_US = Rx-only |
| legal_US = Rx-only |
||
| legal_US_comment = <ref name="Tobradex ointment FDA label" /><ref name="Tobradex drops FDA label" /><ref name="Tobradex ST FDA label" /> |
|||
| legal_status = |
| legal_status = |
||
⚫ | |||
<!--Identifiers--> |
<!--Identifiers--> |
||
| CAS_number_Ref = {{cascite|correct|CAS}} |
|||
| CAS_number = |
| CAS_number = 32986-56-4 |
||
⚫ | |||
| CAS_number2_Ref = {{cascite|correct|CAS}} |
|||
⚫ | |||
| |
| CAS_number2 = 50-02-2 |
||
⚫ | |||
⚫ | |||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|||
| StdInChI = 1S/C22H29FO5.C18H37N5O9/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24;19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3;5-18,24-28H,1-4,19-23H2/t12-,15+,16+,17+,19+,20+,21+,22+;5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m10/s1 |
|||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|||
| StdInChIKey = DWLNMMCXGSKYEM-VQHMUFKESA-N |
|||
| PubChem = |
| PubChem = |
||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = |
| DrugBank = DB00684 |
||
⚫ | |||
⚫ | |||
<!--Chemical data--> |
|||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = VZ8RRZ51VK |
|||
| UNII2_Ref = {{fdacite|correct|FDA}} |
|||
| UNII2 = 7S5I7G3JQL |
|||
| KEGG_Ref = {{keggcite|changed|kegg}} |
|||
| KEGG = D11178 |
|||
| ChEBI_Ref = {{ebicite|correct|EBI}} |
|||
| ChEBI = 28864 |
|||
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
|||
| ChEMBL = 1747 |
|||
}} |
}} |
||
⚫ | '''Tobramycin/dexamethasone''' |
||
⚫ | '''Tobramycin/dexamethasone''', sold under the brand name '''Tobradex''', is a fixed-dose [[combination medication]] in the form of [[eye drops]] and eye [[ointment]], marketed by [[Alcon]].<ref name="Tobradex ointment FDA label" /><ref name="Tobradex drops FDA label" /><ref name="Tobradex ST FDA label" /> The active ingredients are [[tobramycin]] (an [[antibiotic]]) and [[dexamethasone]] (a [[corticosteroid]]).<ref name="Tobradex drops FDA label" /> It is prescribed for the treatment of [[conjunctivitis|pink eye]] in combination with bacterial infections.<ref name="Tobradex drops FDA label" /> |
||
⚫ | |||
⚫ | It is |
||
⚫ | |||
⚫ | |||
⚫ | It is contraindicated with [[Herpetic infection|herpetic]] and other [[viral infection|viral]] eye infections. Other contraindications include [[Mycosis|fungal]] and [[mycobacteria]]l infections because tobramycin is inactive against those, and the corticoid acts as an [[immunosuppressive]] agent, preventing the body's immune system from dealing with the infection. The drops are also contraindicated in patients with [[cornea]]l lesions.<ref name="AustriaCodex">{{cite book|title=Austria-Codex|at=Tobradex-Augentropfen| veditors = Haberfeld H |publisher=Österreichischer Apothekerverlag|location=Vienna|year=2009|edition=2009/2010|isbn=978-3-85200-196-8|language=German}}</ref><ref name="Tobradex ointment FDA label">{{cite web | title=Tobradex- tobramycin and dexamethasone ointment | website=DailyMed | date=24 April 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5538d748-215c-4e3e-b940-ac9baf07d8a1 | access-date=24 September 2020}}</ref><ref name="Tobradex drops FDA label">{{cite web | title=Tobradex- tobramycin and dexamethasone suspension/ drops | website=DailyMed | date=24 April 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22b59456-d26a-4f23-b052-3d73e00181eb | access-date=24 September 2020}}</ref><ref name="Tobradex ST FDA label">{{cite web | title=Tobradex ST- tobramycin / dexamethasone suspension/ drops | website=DailyMed | date=9 September 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1d48422-8cfc-4e9e-a7f8-56c274d8eb83 | access-date=24 September 2020}}</ref> |
||
⚫ | Similarly to other corticosteroid eye drops, [[side |
||
| author = Ch. Faschinger |
|||
⚫ | |||
| date = 3 January 2011 |
|||
⚫ | Similarly to other corticosteroid eye drops, [[side effect]]s include [[hypersensitivity]] and, especially after long-term use, secondary eye infections, [[cataract]] (clouding of the eye lens) and increased [[intraocular pressure]], leading to [[glaucoma]]. Consequently, the drug should not be applied longer than 24 days<ref name="AustriaCodex"/><ref name="ÖAZ">{{cite journal | vauthors = Faschinger C | date = 3 January 2011 | journal = Österreichische Apothekerzeitung | title = TobraDex | issue = 1/2011 | pages = 13 | language = German }}</ref><ref name="Arzneistoff-Profile">{{cite book|title=Arzneistoff-Profile| veditors = Dinnendahl V, Fricke U |publisher=Govi Pharmazeutischer Verlag|location=Eschborn, Germany|year=2010|edition=23|volume=2|isbn=978-3-7741-9846-3|language=German}} |
||
| journal = Österreichische Apothekerzeitung |
|||
</ref> without further medical evaluation.<ref name="Tobradex drops FDA label" /><ref name="Tobradex ST FDA label" /> |
|||
| issue = 1/2011 |
|||
| pages = 13 |
|||
| language = German |
|||
}}</ref><ref name="Arzneistoff-Profile">{{cite book|title=Arzneistoff-Profile|editor=Dinnendahl, V, Fricke, U|publisher=Govi Pharmazeutischer Verlag|location=Eschborn, Germany|date=2010|edition=23|volume=2|isbn=978-3-7741-98-46-3|language=German}}</ref> |
|||
==Interactions== |
==Interactions== |
||
[[Anticholinergic]] eye drops potentiate the risk of increased intraocular pressure. Systemic [[aminoglycoside antibiotic]]s increase toxicity for ears, nerves and kidney.<ref name="AustriaCodex" /> |
[[Anticholinergic]] eye drops potentiate the risk of increased intraocular pressure. Systemic [[aminoglycoside antibiotic]]s increase toxicity for ears, nerves and kidney.<ref name="AustriaCodex" /> |
||
== Brand names == |
|||
Tobrason is a brand name in Jordan.<ref>{{cite web | title = Jordanian Food and Drug Administration | url = http://www.jfda.jo/}}</ref>{{failed verification|date=September 2020}} |
|||
==References== |
==References== |
||
{{reflist}} |
{{reflist}} |
||
== External links == |
|||
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/dexamethasone%20mixture%20with%20tobramycin | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Dexamethasone mixture with tobramycin }} |
|||
{{AminoglycosideAntiBiotics}} |
{{AminoglycosideAntiBiotics}} |
||
{{Corticosteroids}} |
{{Corticosteroids}} |
||
{{Portal bar | Medicine}} |
|||
{{DEFAULTSORT:Tobramycin Dexamethasone}} |
|||
[[Category:Antibiotics]] |
[[Category:Antibiotics]] |
||
[[Category:Glucocorticoids]] |
[[Category:Glucocorticoids]] |
||
[[Category:Combination drugs]] |
[[Category:Combination drugs]] |
||
[[Category:Drugs developed by Novartis]] |
Latest revision as of 00:11, 20 March 2024
Combination of | |
---|---|
Tobramycin | Aminoglycoside antibiotic |
Dexamethasone | Glucocorticoid |
Clinical data | |
Trade names | Tobradex |
AHFS/Drugs.com | Professional Drug Facts |
Routes of administration | Eye drops, topical |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
(what is this?) (verify) |
Tobramycin/dexamethasone, sold under the brand name Tobradex, is a fixed-dose combination medication in the form of eye drops and eye ointment, marketed by Alcon.[1][2][3] The active ingredients are tobramycin (an antibiotic) and dexamethasone (a corticosteroid).[2] It is prescribed for the treatment of pink eye in combination with bacterial infections.[2]
Contraindications
[edit]It is contraindicated with herpetic and other viral eye infections. Other contraindications include fungal and mycobacterial infections because tobramycin is inactive against those, and the corticoid acts as an immunosuppressive agent, preventing the body's immune system from dealing with the infection. The drops are also contraindicated in patients with corneal lesions.[5][1][2][3]
Side effects
[edit]Similarly to other corticosteroid eye drops, side effects include hypersensitivity and, especially after long-term use, secondary eye infections, cataract (clouding of the eye lens) and increased intraocular pressure, leading to glaucoma. Consequently, the drug should not be applied longer than 24 days[5][6][7] without further medical evaluation.[2][3]
Interactions
[edit]Anticholinergic eye drops potentiate the risk of increased intraocular pressure. Systemic aminoglycoside antibiotics increase toxicity for ears, nerves and kidney.[5]
Brand names
[edit]Tobrason is a brand name in Jordan.[8][failed verification]
References
[edit]- ^ a b c "Tobradex- tobramycin and dexamethasone ointment". DailyMed. 24 April 2020. Retrieved 24 September 2020.
- ^ a b c d e f "Tobradex- tobramycin and dexamethasone suspension/ drops". DailyMed. 24 April 2020. Retrieved 24 September 2020.
- ^ a b c d "Tobradex ST- tobramycin / dexamethasone suspension/ drops". DailyMed. 9 September 2019. Retrieved 24 September 2020.
- ^ "Dexamethasone / tobramycin ophthalmic Use During Pregnancy". Drugs.com. 28 November 2018. Retrieved 13 September 2020.
- ^ a b c Haberfeld H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. Tobradex-Augentropfen. ISBN 978-3-85200-196-8.
- ^ Faschinger C (3 January 2011). "TobraDex". Österreichische Apothekerzeitung (in German) (1/2011): 13.
- ^ Dinnendahl V, Fricke U, eds. (2010). Arzneistoff-Profile (in German). Vol. 2 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.
- ^ "Jordanian Food and Drug Administration".
External links
[edit]- "Dexamethasone mixture with tobramycin". Drug Information Portal. U.S. National Library of Medicine.